Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Macrogenics Inc

NASDAQ: MGNX · Life Sciences · 5 alerts · CIK 1125345

Share price
$2.17Close, Nov 16
Market cap
$139M
Shares outstanding
63.91MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Macrogenics Inc filings on SEC EDGAR ↗

4:06 PM ET 8-K
Clinical Trial Data

Macrogenics Clinical Trial Data

MacroGenics announced positive interim Phase 1 data for MGC026, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumors. The study showed a 27% best overall response rate in heavily pretreated SCCHN patients and a manageable safety profile with no treatment-related discontinuations in that cohort. Based on these results, the company plans to initiate a front-line combination study evaluating MGC026 with pembrolizumab.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.